Compare Salesforce Inc (CRM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Sanofi SA — how do they compare? Salesforce Inc trades at $168.69 (market cap $137.23B), while Sanofi SA trades at $43.63 (market cap $102.91B). The key difference: Salesforce Inc is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.6%). Which is the better fit depends on your goals.
| CRM | SNY | |
|---|---|---|
Market Cap | $137.23B | $102.91B |
Sector | Technology | Health |
52-Week High | $270.25 | $52.34 |
52-Week Low | $150.12 | $41.33 |
Enterprise Value | $167.28B | $119.39B |
Dividend Yield | 1.05% | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $168.75, down 1.44% on the day amid a broader tech sell-off. The stock exhibits a neutral technical signal with support near $165 and resistance at $171. Fundamentally, the company shows strong profitability with a 77.64% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven growth potential but also reflects market concerns over software stock volatility.
The outlook remains positive given robust earnings beats, high analyst buy ratings (76.84%), and a consensus price target of $235.90, implying significant upside. Key risks include competitive pressures in AI, macroeconomic sensitivity, and the stock's high valuation multiples. Revenue growth and AI monetization are critical catalysts for future performance.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
